vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and BADGER METER INC (BMI). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $234.1M, roughly 1.2× BADGER METER INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 14.3%, a 82.0% gap on every dollar of revenue. On growth, BADGER METER INC posted the faster year-over-year revenue change (14.1% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 9.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Badger Meter Inc. is a leading global provider of flow measurement and control solutions, serving water utilities, industrial, commercial, and residential customer segments. Its core offerings include smart water meters, IoT-enabled usage monitoring systems, and supporting software that help clients track resource consumption, cut waste, and boost operational efficiency, with key markets spanning North America, Europe, and the Asia-Pacific region.
ACAD vs BMI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $234.1M |
| Net Profit | $273.6M | $33.6M |
| Gross Margin | 90.8% | 39.7% |
| Operating Margin | 6.1% | 18.4% |
| Net Margin | 96.3% | 14.3% |
| Revenue YoY | 9.4% | 14.1% |
| Net Profit YoY | 90.3% | 9.3% |
| EPS (diluted) | $1.61 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $234.1M | ||
| Q3 25 | $278.6M | $222.2M | ||
| Q2 25 | $264.6M | $238.1M | ||
| Q1 25 | $244.3M | $222.2M | ||
| Q4 24 | $259.6M | $205.2M | ||
| Q3 24 | $250.4M | $208.4M | ||
| Q2 24 | $242.0M | $216.7M | ||
| Q1 24 | $205.8M | $196.3M |
| Q4 25 | $273.6M | $33.6M | ||
| Q3 25 | $71.8M | $35.1M | ||
| Q2 25 | $26.7M | $34.6M | ||
| Q1 25 | $19.0M | $38.4M | ||
| Q4 24 | $143.7M | $30.7M | ||
| Q3 24 | $32.8M | $32.0M | ||
| Q2 24 | $33.4M | $33.1M | ||
| Q1 24 | $16.6M | $29.1M |
| Q4 25 | 90.8% | 39.7% | ||
| Q3 25 | 92.2% | 43.1% | ||
| Q2 25 | 92.2% | 41.1% | ||
| Q1 25 | 91.7% | 42.9% | ||
| Q4 24 | 91.6% | 40.3% | ||
| Q3 24 | 92.5% | 40.2% | ||
| Q2 24 | 92.5% | 39.4% | ||
| Q1 24 | 88.8% | 39.3% |
| Q4 25 | 6.1% | 18.4% | ||
| Q3 25 | 12.8% | 20.7% | ||
| Q2 25 | 12.2% | 18.8% | ||
| Q1 25 | 7.9% | 22.2% | ||
| Q4 24 | 59.1% | 19.1% | ||
| Q3 24 | 12.6% | 19.5% | ||
| Q2 24 | 12.6% | 19.2% | ||
| Q1 24 | 7.4% | 18.6% |
| Q4 25 | 96.3% | 14.3% | ||
| Q3 25 | 25.8% | 15.8% | ||
| Q2 25 | 10.1% | 14.5% | ||
| Q1 25 | 7.8% | 17.3% | ||
| Q4 24 | 55.4% | 15.0% | ||
| Q3 24 | 13.1% | 15.4% | ||
| Q2 24 | 13.8% | 15.3% | ||
| Q1 24 | 8.0% | 14.8% |
| Q4 25 | $1.61 | $1.13 | ||
| Q3 25 | $0.42 | $1.19 | ||
| Q2 25 | $0.16 | $1.17 | ||
| Q1 25 | $0.11 | $1.30 | ||
| Q4 24 | $0.86 | $1.04 | ||
| Q3 24 | $0.20 | $1.08 | ||
| Q2 24 | $0.20 | $1.12 | ||
| Q1 24 | $0.10 | $0.99 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $713.3M |
| Total Assets | $1.6B | $973.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | $713.3M | ||
| Q3 25 | $917.3M | $702.5M | ||
| Q2 25 | $822.4M | $677.6M | ||
| Q1 25 | $765.2M | $641.7M | ||
| Q4 24 | $732.8M | $606.2M | ||
| Q3 24 | $577.2M | $591.2M | ||
| Q2 24 | $516.7M | $563.1M | ||
| Q1 24 | $464.0M | $535.6M |
| Q4 25 | $1.6B | $973.6M | ||
| Q3 25 | $1.3B | $978.3M | ||
| Q2 25 | $1.2B | $936.4M | ||
| Q1 25 | $1.1B | $899.6M | ||
| Q4 24 | $1.2B | $816.4M | ||
| Q3 24 | $976.9M | $802.9M | ||
| Q2 24 | $914.1M | $781.3M | ||
| Q1 24 | $855.1M | $743.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $54.8M |
| Free Cash FlowOCF − Capex | — | $50.8M |
| FCF MarginFCF / Revenue | — | 21.7% |
| Capex IntensityCapex / Revenue | — | 1.7% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.63× |
| TTM Free Cash FlowTrailing 4 quarters | — | $169.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $54.8M | ||
| Q3 25 | $74.3M | $51.3M | ||
| Q2 25 | $64.0M | $44.6M | ||
| Q1 25 | $20.3M | $33.0M | ||
| Q4 24 | $40.4M | $52.1M | ||
| Q3 24 | $63.2M | $45.1M | ||
| Q2 24 | $25.0M | $36.4M | ||
| Q1 24 | $29.1M | $21.5M |
| Q4 25 | — | $50.8M | ||
| Q3 25 | $73.9M | $48.2M | ||
| Q2 25 | — | $40.6M | ||
| Q1 25 | — | $30.1M | ||
| Q4 24 | — | $47.4M | ||
| Q3 24 | $63.2M | $42.0M | ||
| Q2 24 | — | $34.1M | ||
| Q1 24 | — | $18.8M |
| Q4 25 | — | 21.7% | ||
| Q3 25 | 26.5% | 21.7% | ||
| Q2 25 | — | 17.1% | ||
| Q1 25 | — | 13.5% | ||
| Q4 24 | — | 23.1% | ||
| Q3 24 | 25.2% | 20.1% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 9.6% |
| Q4 25 | — | 1.7% | ||
| Q3 25 | 0.1% | 1.4% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 0.0% | 1.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | -0.18× | 1.63× | ||
| Q3 25 | 1.03× | 1.46× | ||
| Q2 25 | 2.40× | 1.29× | ||
| Q1 25 | 1.07× | 0.86× | ||
| Q4 24 | 0.28× | 1.70× | ||
| Q3 24 | 1.93× | 1.41× | ||
| Q2 24 | 0.75× | 1.10× | ||
| Q1 24 | 1.76× | 0.74× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
BMI
| Transferred At Point In Time | $198.6M | 85% |
| Transferred Over Time | $22.1M | 9% |
| Other | $13.4M | 6% |
